Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 8/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987843 | 0.89 | GPR119 (0.54) | GPR119CYP4F2CYP4A11HDAC1 | |
| SCHEMBL14191026 | 0.88 | GPR119 (0.68) | GPR119CYP4F2CYP4A11HDAC1CHEK2 | |
| SCHEMBL3987837 | 0.88 | GPR119 (0.51) | GPR119CYP4F2CYP4A11HDAC1ITGB3 | |
| SCHEMBL3983586 | 0.86 | GPR119 (0.56) | GPR119CYP4F2CYP4A11HDAC1 | |
| SCHEMBL3985846 | 0.86 | GPR119 (0.54) | GPR119CYP4F2CYP4A11HDAC1SMN1; SMN2 | |
| SCHEMBL3981092 | 0.85 | GPR119 (0.53) | GPR119CYP4F2CYP4A11 | |
| SCHEMBL3981555 | 0.84 | GPR119 (0.49) | GPR119CYP4F2CYP4A11HDAC1ITGB3 | |
| SCHEMBL3981498 | 0.84 | GPR119 (0.52) | GPR119CYP4F2CYP4A11HDAC1 | |
| SCHEMBL3980490 | 0.79 | CYP4F2 (0.51) | GPR119CYP4F2CYP4A11HDAC1 | |
| SCHEMBL3984718 | 0.79 | GPR119 (0.56) | GPR119CYP4F2CYP4A11CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885CYP4F2 674/4885CYP4A11 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.